Literature DB >> 12542802

Clonal analysis of a human antimouse antibody (HAMA) response.

S J Thorpe1, C Turner, A Heath, I Feavers, I Vatn, J B Natvig, K M Thompson.   

Abstract

Circulating human antimouse antibodies (HAMAs) directed to mouse immunoglobulin G (IgG) are clinically significant, compromising mouse antibody therapy and imaging, and interfering in immunological assays. To investigate the HAMA response, 20 stable cell lines secreting human monoclonal antibodies reactive with mouse IgG were established from a donor with a history of exposure to mice. Their subclass and domain specificities were established by solid-phase binding, indirect haemagglutination assays and immunoblotting, using Igs of known subclass and Ig fragments. The heavy-chain variable region gene usage was determined for 12 HAMAs. Eight HAMAs were IgM, 11 HAMAs were IgG4 and one HAMA was IgG1, indicating an IgG4-dominated response. All of the IgG HAMAs reacted with epitopes present on the Fc portion; one was subclass-specific, nine were subclass-restricted and two were pan-IgG-reactive. Measurement of their affinities gave dissociation constants typically in the nanomolar range. Seven and five HAMAs were derived from variable heavy-chain 3 (VH3) and VH1 gene segments, respectively. The IgG HAMAs used different VH segments to the IgM HAMAs. JH regions were coded by JH4 in eight HAMAs. DH segment usage appeared to be restricted in the IgM HAMAs. Two IgG HAMAs were clonally related. These monoclonal HAMAs are potentially useful as reagents for detecting mouse IgG and as reference reagents for the investigation of the HAMA response in patients undergoing mouse monoclonal antibody therapy and for the investigation of the influence of HAMAs on immunodiagnostic tests.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542802     DOI: 10.1046/j.1365-3083.2003.01189.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

Review 1.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.

Authors:  W W Cheng; T M Allen
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

2.  In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.

Authors:  Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

3.  Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.

Authors:  Judith Niesen; Christoph Stein; Hannes Brehm; Grit Hehmann-Titt; Rolf Fendel; Georg Melmer; Rainer Fischer; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-22       Impact factor: 4.322

4.  Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].

Authors:  Elena Grieger; Gerrit Gresch; Judith Niesen; Mira Woitok; Stefan Barth; Rainer Fischer; Rolf Fendel; Christoph Stein
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-01       Impact factor: 4.322

5.  Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.

Authors:  Jinle Tang; Jialu Li; Xuejun Zhu; Yuan Yu; Dan Chen; Lei Yuan; Zhenyang Gu; Xingding Zhang; Lin Qi; Zhishu Gong; Pengjun Jiang; Juhua Yu; Huimin Meng; Gangli An; Huyong Zheng; Lin Yang
Journal:  Oncotarget       Date:  2016-06-07

6.  Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes.

Authors:  Felista L Tansi; Ronny Rüger; Ansgar M Kollmeier; Markus Rabenhold; Frank Steiniger; Roland E Kontermann; Ulf K Teichgräber; Alfred Fahr; Ingrid Hilger
Journal:  Pharmaceutics       Date:  2020-04-17       Impact factor: 6.321

7.  Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.

Authors:  Mesha Saeed; Sara Zalba; Ann L B Seynhaeve; Reno Debets; Timo L M Ten Hagen
Journal:  Int J Nanomedicine       Date:  2019-03-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.